氢氧混合气辅助治疗64名COVID-19患者的临床报道

氢氧混合气曾经写入新冠肺炎诊疗方案中，但其有效性的证据仍然比较薄弱，因此仍然需要进一步研究，特别是采用严格的多中心双盲安慰剂对照临床试验，只有高质量高级别的临床研究证据，才能作为证明氢气在疾病治疗有效性方面的基础。这也是氢气医学同行们早就达成的共识。关于氢气用于COVID-19患者治疗，上海多家医院的多中心研究结果最近发表。这里摘要翻译介绍给大家，英文摘要同时提供。

Shi M M, Chen Y T, Wang X D, et al. The efficacy of hydrogen/oxygen therapy favored the recovery of omicron SARS-CoV-2 variant infection: results of a multicenter, randomized, controlled trial[J]. Journal of Clinical Biochemistry and Nutrition, 2023: 23-32.

临床研究发现，氢/氧混合吸入对于改善COVID-19患者辅助治疗中的呼吸症状有益。我们旨在探索氢/氧疗法在促进Omicron SARS-CoV-2变体感染恢复方面的有效性。共有64名患者被随机分配接受氢/氧吸入（32名患者）和氧气吸入（32名患者）。氢/氧组中Omicron的平均脱落持续时间比氧气组短。Omicron的累积阴性转化率趋势在第三天后逐渐增加。氢/氧组中的IL-6水平较基线降低了22.8%。在接受氢/氧混合气体吸入后，氢/氧组中的淋巴细胞计数在第3天增加到基线的61.1%。氢/氧组中有更多患者的肺部病变得到解决。我们的研究表明，分子氢在治疗COVID-19患者方面具有有益的趋势，这可能为COVID-19患者的辅助治疗提供一种有前景的解决方案。

关键结果

Clinical studies had found that hydrogen/oxygen mixed inhalation was beneficial to ameliorate the respiratory symptoms in the adjuvant treatment of patients with COVID-19. We aimed to explore the efficacy of hydrogen/oxygen therapy in favoring the recovery of Omicron SARS-CoV-2 variant infection. There were 64 patients who randomly assigned to receive hydrogen/oxygen inhalation (32 patients) and oxygen inhalation (32 patients). The average shedding duration of Omicron in hydrogen/oxygen group was shorter than oxygen group. The trend of cumulative negative conversion rate of Omicron increased gradually after the third day. The IL-6 levels in hydrogen/oxygen group decreased by 22.8% compared with the baseline. After hydrogen/oxygen mixed gas inhalation, the lymphocyte count increased to 61.1% of the baseline on the 3rd day in the hydrogen/oxygen group. More patients in the hydrogen/oxygen group had resolution of pulmonary lesions. Our study showed the beneficial trends of molecular hydrogen in treating patients with COVID-19, which may offer a prospective solution to adjuvant therapy for COVID-19 Patients.

该论文作者主要来自上海交通大学附属瑞金医院、复旦大学附属中山医院和同济大学附属医院等上海多家医疗机构。